AVIGA3 (Cohort 2.0)

Recruiting N/A Interventional Study
Maculopathy
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
50 – 99
Sex
Any
Study type
Interventional
Purpose
Diagnostic
Participants needed
60 (estimated)
Sponsor
Tan Tock Seng Hospital · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Age-Macular Degeneration (AMD) is a common eye condition and a leading cause of vision loss among people age 50 and older. It causes damage to the macula, a small area near the centre of the retina needed for sharp, central vision. It is estimated that the prevalence of early and late AMD in Asian populations aged 40 to 79 were 6.8% and 0.56% respectively. Prevalence in white populations estimated…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion criteria 1. Subjects in the age group ≥ 50 to 99 years old. 2. Both genders 3. Able to understand verbal spoken instructions in British/American English, Chinese or Bahasa Melayu and demonstrate device functionality and implementation. 4. Able to turn on and connect the web-camera to a co…
Contacts

Zheng Kuang, Noel Soh, BSc

+65 6357 3693

zheng.Kuang.soh@nhghealth.com.sg

CONTACT